RT Journal Article
SR Electronic
T1 Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000410
DO 10.1136/jitc-2019-000410
VO 8
IS 1
A1 Cebon, Jonathan S
A1 Gore, Martin
A1 Thompson, John F
A1 Davis, Ian D
A1 McArthur, Grant A
A1 Walpole, Euan
A1 Smithers, Mark
A1 Cerundolo, Vincenzo
A1 Dunbar, P Rod
A1 MacGregor, Duncan
A1 Fisher, Cyril
A1 Millward, Michael
A1 Nathan, Paul
A1 Findlay, Michael P N
A1 Hersey, Peter
A1 Evans, T R Jeffry
A1 Ottensmeier, Christian Hermann
A1 Marsden, Jeremy
A1 Dalgleish, Angus G
A1 Corrie, Pippa G
A1 Maria, Marples
A1 Brimble, Margaret
A1 Williams, Geoff
A1 Winkler, Sintia
A1 Jackson, Heather M
A1 Endo-Munoz, Liliana
A1 Tutuka, Candani S A
A1 Venhaus, Ralph
A1 Old, Lloyd J
A1 Haack, Dennis
A1 Maraskovsky, Eugene
A1 Behren, Andreas
A1 Chen, Weisan
YR 2020
UL http://jitc.bmj.com/content/8/1/e000410.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.